Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsRyan Wong is recorded as CFO at Sarepta Therapeutics, Inc. (SRPT). Sarepta Therapeutics, Inc. reported in an 8-K filed July 16, 2025 that Ryan Wong was appointed Executive Vice President, Chief Financial Officer, effective July 16, 2025. Ryan Wong has spoken on 5 earnings calls and 1 other investor event across 1 company, most recently for Sarepta Therapeutics, Inc. on November 5, 2026. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sarepta Therapeutics, Inc. includes Douglas Ingram (CEO and Board Member), Michael Severino, M.D. (CEO and Board Member), M. Kathleen Behrens (Chairman) and 7 others.
“On July 14, 2025, the Board appointed Ian Estepan as the Company's President and Chief Operating Officer, Louise Rodino-Klapac, Ph.D. as the Company's President, Research and Development and Technical Operations, and Ryan Wong as the Company's Executive Vice President, Chief Financial Officer, each effective as of July 16, 2025.”
“In the third quarter, we executed against our financial strategy, driving meaningful revenue while maintaining expense discipline as we invested in our pipeline.”
“We delivered a strong financial performance in the second quarter, and we are pleased with the continued operating discipline reflected across the business.”
“It didn't seem like the markets really fully discounted both the risks that I think were happening previously and now I think a very strong tailwind now because of that exact point that you're making in terms of predictability.”
“On behalf of the Disrupted team, I'm pleased to report a strong quarter of financial execution to start the year, where our base business was profitable and cash flow positive.”
“Provided details for the fourth quarter and full year on a GAAP basis, as well as a non-GAAP basis. Please leave this available on Disrupted's website for a full review of financial results.”
Biotechnology · Healthcare
CFO
